Information:
Error:
ID
23475
Description
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV; ODM derived from: https://clinicaltrials.gov/show/NCT00516685
Link
https://clinicaltrials.gov/show/NCT00516685
Keywords
Versions (1)
- 7/6/17 7/6/17 -
Uploaded on
July 6, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV NCT00516685
Eligibility Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV NCT00516685
- StudyEvent: Eligibility
Similar models
Eligibility Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV NCT00516685
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
patients who have signed the informed consent form.
boolean
C0021430 (UMLS CUI [1])
ID.2
Item
patients who are eighteen years of age or over with histologically or cytologically confirmed nsclc in advanced stages iiib or iv, not amenable to any attempt of curative chemo-radiotherapy and/or surgery.
boolean
C0001779 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0877373 (UMLS CUI [1,3])
C0007131 (UMLS CUI [1,2])
C0877373 (UMLS CUI [1,3])
ID.3
Item
patients with measurable lesions, defined as those measurable at least in one dimension (refered to higher diameter) and with a diameter equal or higher 20 mm using conventional techniques (pet, ct scan, mri, rx) or equal or higher 10 mm using ct scan.
boolean
C0221198 (UMLS CUI [1])
ID.4
Item
patients who have finished their last cycle of chemotherapy and/or radiotherapy not less than 4 weeks prior to randomization and not more than 8 weeks.
boolean
C0392920 (UMLS CUI [1,1])
C1522449 (UMLS CUI [1,2])
C1522449 (UMLS CUI [1,2])
ID.5
Item
female patients of reproductive potential must have negative pregnancy tests. those female volunteers admitted to the study must be using a reliable means of contraception such as tubal ligation, oral contraceptive or iud.
boolean
C0032961 (UMLS CUI [1,1])
C0009862 (UMLS CUI [1,2])
C0009862 (UMLS CUI [1,2])
ID.6
Item
ecog status 0 to 2.
boolean
C1520224 (UMLS CUI [1])
ID.7
Item
patients with normal organ and bone marrow function, as defined by the parameters in accordance to that provided by the normal lab reference range.
boolean
C0678852 (UMLS CUI [1])
ID.8
Item
patients with no evidence of objective disease progression, 1 month after finishing first line chemotherapy as per recist.
boolean
C0242656 (UMLS CUI [1])
ID.9
Item
patients who are candidates for combined modality treatment.
boolean
C0009429 (UMLS CUI [1])
ID.10
Item
patients who are receiving immunosuppressive therapy including corticosteroids.
boolean
C0021081 (UMLS CUI [1])
ID.11
Item
patients who have received immunotherapy within the previous 3 months.
boolean
C0021081 (UMLS CUI [1])
ID.12
Item
patients who have participated in a clinical study within the previous 30 days.
boolean
C0008976 (UMLS CUI [1])
ID.13
Item
patients who may be allergic to any component of the vaccine.
boolean
C0020517 (UMLS CUI [1])
ID.14
Item
medical reasons considered by the investigators as disqualification from the study such as significant uncontrolled co-morbid disease or potential non-compliance with the protocol.
boolean
C0012634 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,2])
ID.15
Item
patients bearing brain metastasis from the primary lung tumor.
boolean
C0220650 (UMLS CUI [1])
ID.16
Item
patients bearing a second primary tumor.
boolean
C0677930 (UMLS CUI [1])
ID.17
Item
patients showing progressive disease after finishing first line chemotherapy.
boolean
C0677932 (UMLS CUI [1])